Dr Reddy’s Lab Q2 FY22 Results: Pharma major reports 30% growth in profit, stock up nearly 7%

Pharmaceutical company Dr Reddy's Laboratories has reported healthy quarterly figures on an annual basis during the second quarter of fiscal 2021-22 (Q2FY22). Almost on all fronts, the company has reported double-digit growth during the quarter.

Dr Reddy's Lab consolidated earnings grew 30 percent year on year to Rs 992 crore in Q2FY22 compared to Rs 762.3 crore in the same period a year ago. While the company's consolidated revenue increased 18 percent year-on-year to Rs 5,763 crore versus Rs 4,987 crore in the corresponding quarter a year ago.

Watch Zee Business Live TV broadcast below:

Likewise, the major drugmaker has also reported growth in EBITDA, which has risen nearly 23 percent year-on-year to Rs 1,557 crore in the July-September quarter of FY22 versus Rs 1,267 crore in the second. quarter of fiscal 21. And, the margin has increased 110 basis points to 27% from 25.9% year-over-year during the quarter.

Dr Reddy's shares have been trading close to 7 percent higher at Rs 4878 per share on the intraday BSE today, immediately after the earnings announcement. It had reached 4,915 rupees per share at the latest on the BSE today.